Hologic acquires SOMATEX, a leader in biopsy site markers and localization technologies
The MedTech company Hologic, with a primary focus on women’s health, has acquired SOMATEX Medical Technologies, a leader in biopsy site markers and localization technologies, for approximately $64 million. The company was previously owned by E-Med Solutions, Berlin, a group of investors led by German private equity company Westlake Partners.
The transaction supports Hologic’s strategy to provide a comprehensive suite of innovative solutions across the continuum of breast health care. Specifically, SOMATEX’s differentiated products will enable Hologic to strengthen and further expand its breast marker portfolio, which has been growing consistently. As a result of the acquisition, Hologic will also enhance its sales presence in Europe by expanding its direct channel in Germany and its network of regional and international distributor partners.
“The acquisition of SOMATEX allows us to expand our biopsy portfolio by providing a suite of marketleading solutions that not only address our customers’ needs, but also improve the biopsy experience for their patients,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “We’ve had a strong partnership with SOMATEX for several years, which along with our shared focus on innovation, will allow us to quickly integrate and begin building a pipeline that will drive profitable growth and recurring revenue for our breast health business globally.”
SOMATEX specializes in the development and manufacturing of minimally invasive devices in the areas of tumour diagnostics, biopsy and interventional specialties, providing Hologic with additional expertise and capabilities to continue to grow its breast health portfolio. The SOMATEX product portfolio includes the Tumark family of tissue markers, which were distributed by Hologic in the U.S. prior to the acquisition.
